Abcellera Biologics vs OmniAb: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Abcellera Biologics Inc (ABCL)

Q3 202617 Jun – 11 Aug 2026

▲2▼1

AbCellera's hot-flash drug success and Jazz deal offset weak Q2

Jazz partnership brings $56M upfront and up to $792M per program AbCellera signed a deal with Jazz Pharmaceuticals for two antibody programs for solid tumors, receiving $56 million upfront and potentially $792 million per program in milestones plus royalties. This validates its technology and adds non-dilutive cash, supporting the stock.
This is a new partnership that directly boosts AbCellera's cash and validates its platform, driving positive sentiment.
Q2 loss widens to $55M as revenue falls to $4M AbCellera reported a wider net loss of $55 million and revenue dropped to $4 million from $17 million a year ago. The company also missed its internal goal of moving another program into IND-enabling activities, raising concerns about execution.
This is a new financial report showing deteriorating results, which weighs on the stock price.
ABCL635 Phase 2 success sends stock up over 30% AbCellera's hot-flash drug ABCL635 met primary endpoints in a Phase 2 trial, reducing symptoms by 83% versus 33% for placebo with no serious side effects. The stock surged over 30%, as the drug could be a non-hormonal blockbuster.
This is a major clinical win that directly caused a large stock jump and improves the company's pipeline prospects.

July 202617 Jun – 11 Aug 2026

▲2▼1

AbCellera's hot-flash drug success and Jazz deal offset weak Q2

Jazz partnership brings $56M upfront and up to $792M per program AbCellera signed a deal with Jazz Pharmaceuticals for two antibody programs for solid tumors, receiving $56 million upfront and potentially $792 million per program in milestones plus royalties. This validates its technology and adds non-dilutive cash, supporting the stock.
This is a new partnership that directly boosts AbCellera's cash and validates its platform, driving positive sentiment.
Q2 loss widens to $55M as revenue falls to $4M AbCellera reported a wider net loss of $55 million and revenue dropped to $4 million from $17 million a year ago. The company also missed its internal goal of moving another program into IND-enabling activities, raising concerns about execution.
This is a new financial report showing deteriorating results, which weighs on the stock price.
ABCL635 Phase 2 success sends stock up over 30% AbCellera's hot-flash drug ABCL635 met primary endpoints in a Phase 2 trial, reducing symptoms by 83% versus 33% for placebo with no serious side effects. The stock surged over 30%, as the drug could be a non-hormonal blockbuster.
This is a major clinical win that directly caused a large stock jump and improves the company's pipeline prospects.

Latest17 Jun – 11 Aug 2026

▲2▼1

AbCellera's hot-flash drug success and Jazz deal offset weak Q2

Jazz partnership brings $56M upfront and up to $792M per program AbCellera signed a deal with Jazz Pharmaceuticals for two antibody programs for solid tumors, receiving $56 million upfront and potentially $792 million per program in milestones plus royalties. This validates its technology and adds non-dilutive cash, supporting the stock.
This is a new partnership that directly boosts AbCellera's cash and validates its platform, driving positive sentiment.
Q2 loss widens to $55M as revenue falls to $4M AbCellera reported a wider net loss of $55 million and revenue dropped to $4 million from $17 million a year ago. The company also missed its internal goal of moving another program into IND-enabling activities, raising concerns about execution.
This is a new financial report showing deteriorating results, which weighs on the stock price.
ABCL635 Phase 2 success sends stock up over 30% AbCellera's hot-flash drug ABCL635 met primary endpoints in a Phase 2 trial, reducing symptoms by 83% versus 33% for placebo with no serious side effects. The stock surged over 30%, as the drug could be a non-hormonal blockbuster.
This is a major clinical win that directly caused a large stock jump and improves the company's pipeline prospects.

OmniAb Inc. (OABI)

Q3 20267 Aug – 28 Aug 2026

▲4

OmniAb's revenue jump, raised guidance, and Lilly deal boost cash outlook

Q2 revenue surges 243%, loss narrows, guidance raised OmniAb's second-quarter revenue jumped to $13.4 million from $3.9 million a year earlier, and its net loss shrank to $5.9 million from $15.9 million. Management raised full-year 2026 revenue guidance to $32–36 million. This shows the business is growing and losing less money, which supports a higher stock price.
This is the core financial result that directly improves OABI's earnings outlook and investor confidence.
Eli Lilly ion channel deal adds up to $370M in milestones OmniAb signed a global collaboration with Eli Lilly for an ion channel program. OmniAb gets an upfront payment and could receive up to $370 million in milestone payments plus royalties on sales. This validates OmniAb's technology and brings in cash without selling new shares, which is good for the stock.
The Lilly deal is a major new partnership that boosts OmniAb's cash and credibility, directly affecting its valuation.
Cash forecast raised to $49–53 million on licensing deals OmniAb now expects to end 2026 with $49–53 million in cash, up from a prior $37–41 million estimate, thanks to recent licensing deals including Lilly. More cash means the company can fund operations longer without needing to raise money by selling stock, which reduces risk for shareholders.
The higher cash outlook directly addresses funding concerns and lowers the risk of dilution, a key driver for a small biotech stock.
New partner agreements with Argenx and Rosa Therapeutics OmniAb signed new agreements with Argenx and Rosa Therapeutics, adding to its 110 active partners and 425 active programs. Growing demand for its antibody discovery platforms shows the business can keep attracting partners, which supports future milestone revenue and stock price.
New partnerships signal growing platform demand, a key long-term growth driver for OmniAb.

August 20267 Aug – 28 Aug 2026

▲4

OmniAb's revenue jump, raised guidance, and Lilly deal boost cash outlook

Q2 revenue surges 243%, loss narrows, guidance raised OmniAb's second-quarter revenue jumped to $13.4 million from $3.9 million a year earlier, and its net loss shrank to $5.9 million from $15.9 million. Management raised full-year 2026 revenue guidance to $32–36 million. This shows the business is growing and losing less money, which supports a higher stock price.
This is the core financial result that directly improves OABI's earnings outlook and investor confidence.
Eli Lilly ion channel deal adds up to $370M in milestones OmniAb signed a global collaboration with Eli Lilly for an ion channel program. OmniAb gets an upfront payment and could receive up to $370 million in milestone payments plus royalties on sales. This validates OmniAb's technology and brings in cash without selling new shares, which is good for the stock.
The Lilly deal is a major new partnership that boosts OmniAb's cash and credibility, directly affecting its valuation.
Cash forecast raised to $49–53 million on licensing deals OmniAb now expects to end 2026 with $49–53 million in cash, up from a prior $37–41 million estimate, thanks to recent licensing deals including Lilly. More cash means the company can fund operations longer without needing to raise money by selling stock, which reduces risk for shareholders.
The higher cash outlook directly addresses funding concerns and lowers the risk of dilution, a key driver for a small biotech stock.
New partner agreements with Argenx and Rosa Therapeutics OmniAb signed new agreements with Argenx and Rosa Therapeutics, adding to its 110 active partners and 425 active programs. Growing demand for its antibody discovery platforms shows the business can keep attracting partners, which supports future milestone revenue and stock price.
New partnerships signal growing platform demand, a key long-term growth driver for OmniAb.

Latest7 Aug – 28 Aug 2026

▲4

OmniAb's revenue jump, raised guidance, and Lilly deal boost cash outlook

Q2 revenue surges 243%, loss narrows, guidance raised OmniAb's second-quarter revenue jumped to $13.4 million from $3.9 million a year earlier, and its net loss shrank to $5.9 million from $15.9 million. Management raised full-year 2026 revenue guidance to $32–36 million. This shows the business is growing and losing less money, which supports a higher stock price.
This is the core financial result that directly improves OABI's earnings outlook and investor confidence.
Eli Lilly ion channel deal adds up to $370M in milestones OmniAb signed a global collaboration with Eli Lilly for an ion channel program. OmniAb gets an upfront payment and could receive up to $370 million in milestone payments plus royalties on sales. This validates OmniAb's technology and brings in cash without selling new shares, which is good for the stock.
The Lilly deal is a major new partnership that boosts OmniAb's cash and credibility, directly affecting its valuation.
Cash forecast raised to $49–53 million on licensing deals OmniAb now expects to end 2026 with $49–53 million in cash, up from a prior $37–41 million estimate, thanks to recent licensing deals including Lilly. More cash means the company can fund operations longer without needing to raise money by selling stock, which reduces risk for shareholders.
The higher cash outlook directly addresses funding concerns and lowers the risk of dilution, a key driver for a small biotech stock.
New partner agreements with Argenx and Rosa Therapeutics OmniAb signed new agreements with Argenx and Rosa Therapeutics, adding to its 110 active partners and 425 active programs. Growing demand for its antibody discovery platforms shows the business can keep attracting partners, which supports future milestone revenue and stock price.
New partnerships signal growing platform demand, a key long-term growth driver for OmniAb.